Latest news with #WestPharmaceutical
Yahoo
2 days ago
- Business
- Yahoo
Is West Pharmaceutical Services, Inc. (NYSE:WST) Potentially Undervalued?
West Pharmaceutical Services, Inc. (NYSE:WST) saw a decent share price growth of 11% on the NYSE over the last few months. The recent rally in share prices has nudged the company in the right direction, though it still falls short of its yearly peak. As a large-cap stock with high coverage by analysts, you could assume any recent changes in the company's outlook is already priced into the stock. However, could the stock still be trading at a relatively cheap price? Today we will analyse the most recent data on West Pharmaceutical Services's outlook and valuation to see if the opportunity still exists. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The stock seems fairly valued at the moment according to our valuation model. It's trading around 11% below our intrinsic value, which means if you buy West Pharmaceutical Services today, you'd be paying a fair price for it. And if you believe the company's true value is $236.69, then there's not much of an upside to gain from mispricing. Is there another opportunity to buy low in the future? Since West Pharmaceutical Services's share price is quite volatile, we could potentially see it sink lower (or rise higher) in the future, giving us another chance to buy. This is based on its high beta, which is a good indicator for how much the stock moves relative to the rest of the market. See our latest analysis for West Pharmaceutical Services Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. West Pharmaceutical Services' earnings over the next few years are expected to increase by 32%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? WST's optimistic future growth appears to have been factored into the current share price, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at the stock? Will you have enough confidence to invest in the company should the price drop below its fair value? Are you a potential investor? If you've been keeping an eye on WST, now may not be the most optimal time to buy, given it is trading around its fair value. However, the positive outlook is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. It can be quite valuable to consider what analysts expect for West Pharmaceutical Services from their most recent forecasts. At Simply Wall St, we have the analysts estimates which you can view by clicking here. If you are no longer interested in West Pharmaceutical Services, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Associated Press
2 days ago
- Business
- Associated Press
ROSEN, LEADING INVESTOR COUNSEL, Encourages West Pharmaceutical Services, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 01, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of West Pharmaceutical Services, Inc. (NYSE: WST) between February 16, 2023 and February 12, 2025, both dates inclusive (the 'Class Period'), of the important July 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased West common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the West class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, throughout the Class Period, defendants made false and misleading statements and/or failed to disclose that: (1) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products ('HVP') portfolio; (2) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to West's profit margins due to operational inefficiencies; (3) these margin pressures created the risk of costly restructuring activities, including West's exit from continuous glucose monitoring ('CGM') contracts with long-standing customers; and (4) as a result of the foregoing, defendants' positive statements about West's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the West class action, go to call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ------------------------------- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Yahoo
4 days ago
- Business
- Yahoo
West Pharmaceutical Services, Inc. (WST): A Bull Case Theory
We came across a bullish thesis on West Pharmaceutical Services, Inc. (WST) on Swiss Transparent Portfolio's Substack. In this article, we will summarize the bulls' thesis on WST. West Pharmaceutical Services, Inc. (WST)'s share was trading at $208.49 as of 22nd May. WST's trailing and forward P/E were 32.73 and 34.36respectively according to Yahoo Finance. A close-up of a technician working on a liquid injectable in a modern industrial lab. West Pharmaceutical Services stands out as a durable, underappreciated leader in the critical niche of injectable drug packaging. Despite recent headwinds from a post-Covid inventory glut and short-term earnings softness, the company's fundamentals remain strong. West holds a near-monopoly in a mission-critical industry with high switching costs, secular growth drivers like biologics and GLP-1 therapies, and a conservative, high-quality management team. Its financial turbulence appears transient, offering long-term investors an opportunity to accumulate shares at a fair price. While the current ~32x forward P/E may appear elevated, it's based on temporarily depressed earnings; normalized multiples suggest a more reasonable valuation. West's strategic investments during the downturn — including capacity expansion and share repurchases — reinforce its long-term potential. Risks such as customer concentration, technological disruption, execution missteps, regulatory issues, and macroeconomic volatility are real but manageable. The company's embedded role in drug delivery makes sudden disruptions unlikely, and its century-long record of quality execution offers confidence. Scenario analysis shows a compelling risk/reward balance: the bull case projects a ~15% CAGR, while even the bear case requires a confluence of major setbacks to yield sustained losses. West is not a flashy growth story but rather a compounder built on operational excellence, customer entrenchment, and resilient demand. For investors comfortable with a mid-30s P/E as a reflection of quality, West offers a rare blend of safety and growth. It's a Rolls-Royce business at a Bentley price — a quiet engine of compounding that, barring major failure, should keep running reliably for years to come. West Pharmaceutical Services, Inc. (WST) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held WST at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the risk and potential of WST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than WST but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Associated Press
4 days ago
- Business
- Associated Press
Class Action Filed Against West Pharmaceutical Services, Inc. (WST) - July 7, 2025 Deadline to Join – Contact Levi & Korsinsky
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in West Pharmaceutical Services, Inc. ('West Pharmaceutical Services, Inc.' or the 'Company') (NYSE: WST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of West Pharmaceutical Services, Inc. investors who were adversely affected by alleged securities fraud between February 16, 2023 and February 12, 2025. Follow the link below to get more information and be contacted by a member of our team: WST investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin HVP portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with longstanding customers; and (d) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis. WHAT'S NEXT? If you suffered a loss in West Pharmaceutical Services, Inc. during the relevant time frame, you have until July 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171
Yahoo
5 days ago
- Business
- Yahoo
West Pharmaceutical Services, Inc. (WST): A Bull Case Theory
We came across a bullish thesis on West Pharmaceutical Services, Inc. (WST) on Swiss Transparent Portfolio's Substack. In this article, we will summarize the bulls' thesis on WST. West Pharmaceutical Services, Inc. (WST)'s share was trading at $208.49 as of 22nd May. WST's trailing and forward P/E were 32.73 and 34.36respectively according to Yahoo Finance. A close-up of a technician working on a liquid injectable in a modern industrial lab. West Pharmaceutical Services stands out as a durable, underappreciated leader in the critical niche of injectable drug packaging. Despite recent headwinds from a post-Covid inventory glut and short-term earnings softness, the company's fundamentals remain strong. West holds a near-monopoly in a mission-critical industry with high switching costs, secular growth drivers like biologics and GLP-1 therapies, and a conservative, high-quality management team. Its financial turbulence appears transient, offering long-term investors an opportunity to accumulate shares at a fair price. While the current ~32x forward P/E may appear elevated, it's based on temporarily depressed earnings; normalized multiples suggest a more reasonable valuation. West's strategic investments during the downturn — including capacity expansion and share repurchases — reinforce its long-term potential. Risks such as customer concentration, technological disruption, execution missteps, regulatory issues, and macroeconomic volatility are real but manageable. The company's embedded role in drug delivery makes sudden disruptions unlikely, and its century-long record of quality execution offers confidence. Scenario analysis shows a compelling risk/reward balance: the bull case projects a ~15% CAGR, while even the bear case requires a confluence of major setbacks to yield sustained losses. West is not a flashy growth story but rather a compounder built on operational excellence, customer entrenchment, and resilient demand. For investors comfortable with a mid-30s P/E as a reflection of quality, West offers a rare blend of safety and growth. It's a Rolls-Royce business at a Bentley price — a quiet engine of compounding that, barring major failure, should keep running reliably for years to come. West Pharmaceutical Services, Inc. (WST) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held WST at the end of the fourth quarter which was 31 in the previous quarter. While we acknowledge the risk and potential of WST as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than WST but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
